Biochemistry

Aston University

Subscriber access provided by Aston University Library & Information Services

Article

Photoaffinity cross-linking and unnatural amino acid mutagenesis reveal insights into calcitonin gene-related peptide binding to the calcitonin receptor-like receptor/ receptor activity-modifying protein 1 (CLR/RAMP1) complex

John Simms, Romez Uddin, Thomas P. Sakmar, Joseph J. Gingell, Michael L. Garelja, Debbie L. Hay, Margaret A. Brimble, Paul W. R. Harris, Christopher Arthur Reynolds, and David R. Poyner

Biochemistry, **Just Accepted Manuscript** • DOI: 10.1021/acs.biochem.8b00502 • Publication Date (Web): 13 Jul 2018

Downloaded from http://pubs.acs.org on July 17, 2018

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

ACS Publications

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For Table of Contents use only

338x190mm (96 x 96 DPI)

Photoaffinity cross-linking and unnatural amino acid mutagenesis reveal insights into calcitonin gene-related peptide binding to the calcitonin receptor-like receptor/receptor activity-modifying protein 1 (CLR/RAMP1) complex

John Simms[1,2], Romez Uddin[1], Thomas P. Sakmar[3], Joseph J. Gingell[4], Michael L. Garelja[4], Debbie L. Hay[4], Margaret A. Brimble[4], Paul W. Harris[4], Christopher A. Reynolds[5] and David R. Poyner[1]*

[1]Aston University, Birmingham, B4 7ET, UK; [2]Coventry University, Priory St., Coventry, CV1 5FB, UK; [3]The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA; [4] University of Auckland, 3A Symonds Street, Auckland, 1010, New Zealand and [5]University of Essex, Wivenhoe Park, Colchester, CO4 3SQ, UK.

*Corresponding author: David R. Poyner, Mail d.r.poyner@aston.ac.uk, Tel. +44 (0)121 204 3997

Abbreviations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

azF-p-azido L-phenylalanine, AM – adrenomedullin, CGRP – calcitonin gene-related peptide, CLR – calcitonin receptor-like receptor, CT - calcitonin, Dde - 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl DMF-dimethyl formamide, ECD – extracellular domain, ECL-extracellular loop, GLP-1 – glucagon-like peptide-1, GPCR – G protein-coupled receptor, RAMP – receptor activity modifying protein, TM - transmembrane

Short title; Binding of CGRP to its receptor

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Calcitonin gene-related peptide (CGRP) binds to the complex of the calcitonin receptor-like receptor (CLR) with receptor activity-modifying protein 1 (RAMP1). It remains unclear how CGRP interacts with the transmembrane domain (including the extracellular loops) of this family B receptor. In the current study, a photoaffinity cross linker, p-azido L-phenylalanine (azF) was incorporated into CLR, chiefly in the second extracellular loop (ECL2) using genetic code expansion and unnatural amino acid mutagenesis. The method was optimised to ensure efficient photolysis of azF residues near to the transmembrane bundle of the receptor. A CGRP analogue modified with fluorescein at position 15 was used for detection of uv-induced cross-linking. The methodology was verified by confirming the known contacts of CGRP to the extracellular domain of CLR. Within ECL2, the chief contacts were I284 on the loop itself and L291, at the top of the 5th transmembrane helix (TM5). Minor contacts were noted along the lip of ECL2 between S286 and L290 and also with M223 in TM3 and F349 in TM6. Full length molecular models of the bound receptor complex suggest that CGRP sits at the top of the TM bundle, with Thr6 of the peptide making contacts with L291 and H295. I284 is likely to contact Leu12 and Ala13 of CGRP, and Leu16 of CGRP is at the ECL/extracellular domain (ECD) boundary of CLR. Reduced potency, E_{max} and affinity of [Leu16Ala]-human alpha CGRP is consistent with this model. Contacts between Thr6 of CGRP and H295 may be particularly important for receptor activation.

KEYWORDS

G protein-coupled receptor, Receptor activity-modifying proteins, calcitonin receptor-like receptor, unnatural amino acid mutagenesis, calcitonin gene-related peptide

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Calcitonin gene-related peptide (CGRP) is an abundant sensory neuropeptide; it is known to be a very potent vasodilator and is implicated in migraine. It is part of the calcitonin superfamily of peptides which also includes adrenomedullin, adrenomedullin 2/intermedin and amylin[1, 2]. The peptides all bind to family B/secretin-like G protein-coupled receptors; either the calcitonin receptor or the calcitonin receptor-like receptor (CLR). However, for high affinity binding for all of these ligands apart from calcitonin, it is necessary for the receptor to form a complex with a second transmembrane protein from the receptor activity-modifying protein (RAMP) family with only three members. The CGRP receptor is formed from CLR and RAMP1, although CGRP will also bind with high affinity to the complex of the calcitonin receptor and RAMP1[1].

The binding of endogenous peptide ligands to family B GPCRs generally follows the two domain model where the N-terminal tail of the peptide interacts with the transmembrane (TM) domain of the receptor whereas the C-terminal tail binds to the extracellular domain (ECD) of the receptor.[3] Recently a number of structures of full length family B GPCRs have been published, namely for the glucagon and glucagon-like peptide 1 (GLP-1) receptors.[4-8] The full length calcitonin receptor has been visualised by cryo-electron microscopy but the ECD of the receptor was very flexible and so could not be resolved. The bound salmon calcitonin peptide was also poorly resolved and its binding mode was only refined by rigid body fitting of the calcitonin receptor ECD structure (PDB code 5II0) and confirmed with data from mutagenesis.[9] For the CGRP receptor, a crystal structure is available showing the C-terminal tail of a CGRP analogue bound to the ECDs of CLR and RAMP1.[10] Extensive mutagenesis data are available which has allowed the construction of models of how CGRP

interacts with the TM domain of the receptor[11-15]. These studies have implicated extracellular loop 2 (ECL2) of CLR as being especially important for CGRP binding[12-14]. However, direct evidence of molecular contacts between ligand and receptor is lacking.

Photoaffinity cross-linking has long been used to map the binding of ligands to receptors[16]. Conventionally a photoaffinity cross-linker is incorporated into the ligand; this then requires extensive peptide mapping to identify the most likely contact point on the receptor. With the use of genetic code expansion and unnatural amino acid mutagenesis[17], it is now possible to incorporate the photoaffinity cross-linker into the receptor, thereby eliminating the need for peptide mapping or sequencing to identify contact points on the receptor. This general approach, known as targeted photo-cross-linking[18], has been used to map ligand-receptor interactions in a number of GPCRs, including the neurokinin NK-1 receptor[19], ghrelin receptor[20], type 1 receptor for the corticotropin releasing factor (CRF1R)[21-23] and GLP-1 receptor[24]. This has not yet been extensively applied to a complex dimeric receptor, such as the CGRP receptor. In the current study, we have developed a modified targeted-photo-cross-linking strategy to study ECL2 of CLR and have identified two major contact points for CGRP: I284 and L291.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

Materials - Human alpha CGRP was from Bachem (St. Helens, UK). CGRP analogues were synthesised as indicated below. Alpha Screen, LANCE cAMP assay kits, reagents, plates, and [^{125}I]-human iodohistidyl^{10}-αCGRP were purchased from PerkinElmer (Waltham, MA, USA).

Peptide synthesis - [Lys(5,(6)-carboxyfluorescein)^{15}]-alpha-CGRP, [Leu^{12}]-alpha-CGRP and [Leu^{16}]-alpha-CGRP were synthesised by solid phase peptide synthesis using the Fmoc/^{t}Bu method on a 0.1 mmol scale largely as described previously[25]. Briefly, Rink amide ChemMatrix resin (0.48 mmol/g) was elongated using a PS3 (Protein Technologies, Tucson, Arizona, USA) automated peptide synthesiser. The Fmoc group was removed with 20% piperidine in dimethyl formamide (DMF) (v/v), 2 x 5 min and the Fmoc amino acids were coupled for 20 min using 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate and *N,N*-diisopropylethylamine. A pseudoproline, Fmoc-Leu-Ser[ψ-^{Me,Me})Pro] was used at position 16/17 to increase synthetic efficiency.[26] To enable incorporation of the 5,(6)-carboxyfluorescein to a side chain amine, Leu-15 was substituted with Lys(Dde) (Dde = 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl). Boc-alanine was used as the N-terminal amino acid.

Following chain assembly, on-resin removal of the Dde group on Lys^{15} was accomplished with 2% hydrazine hydrate in DMF (v/v) 2 x 3 min and 5,(6)-carboxyfluorescein was coupled with *N,N'*-diisopropylcarbodiimide/ 1-hydroxybenzotriazole overnight. The resin was then treated with 20% piperidine in DMF (v/v) 4 x 5 min to remove excess 5,(6)-carboxyfluorescein.[27] The crude peptide was cleaved from the resin with concomitant

removal of side chain protecting groups with 94% trifluoroacetic acid, 1% triisopropylsilane, 2.5% water and 2.5% ethane dithiol (v/v/v/v) for 3 h, precipitated with cold diethyl ether, isolated by centrifugation, dissolved in 50% aqueous acetonitrile containing 0.1% trifluoroacetic acid and lyophilised to afford 228 mg of crude peptide. The crude fluorescently labelled alpha-CGRP was analysed by LC-MS (Calc. mass 4165.33, found mass 4163.30±0.9 Da) and then purified by sample displacement chromatography[28] on a C18 Gemini (Phenomenex) column (10 x 250 mm) at a flow rate of 5 ml/min at 50 °C to give 25.1 mg of pure linear (unoxidised) [Lys(5,(6)-carboxyfluorescein)[15]]-alpha-CGRP.

The linear peptide (25 mg) was dissolved in 0.1 M Tris-HCl (pH 7.85) at a concentration of 1 mg/ml and the oxidation (disulfide formation) allowed to proceed at room temperature open to air. Monitoring by reverse phase HPLC indicated that the reaction was complete after 5 h. The reaction mixture was acidified to pH=2, diluted with water (60 ml) and purified by semi-preparative reverse phase HPLC using a C18 Gemini column (10 x 250 mm) at a flow rate of 5 ml/min at 50 °C and eluted using an appropriate gradient based on the analytical HPLC profile. Fractions containing the pure peptide were identified by electrospray mass spectrometry and/or HPLC, pooled and lyophilised to give [Lys(5,(6)-carboxyfluorescein)[15]]-alpha CGRP > 95% purity as judged by integration of the HPLC chromatogram at 210nm (Calc. mass 4163.31, Found mass 4162.20±0.5 Da).

Unnatural amino acid mutagenesis and cross-linking strategy - Unnatural amino acid mutagenesis was performed in HEK293T cells as described previously[24, 29], using amber mutant human CLR, myc-tagged RAMP1, suppressor tRNA, and azF amino-acyl tRNA synthetase but with some modifications. HEK293T cells were seeded to a density of 800,000 cells per well (resulting in 70% cell confluence the next day) of a 6-well plate. Twenty-four

hrs after seeding, the cells were transfected with a DNA cocktail comprising 1 µg mutated/WT receptor, 1 µg suppressor tRNA and 0.5 µg aminoacyl tRNA synthetase using lipofectamine (Life Technologies #18324-012) as per the manufacturer's instructions. 4 hrs post transfection the media was replaced with Dulbecco's modified Eagle medium (DMEM) supplemented with 20%v/v FBS and 1 mM azF, which itself was subsequently replaced after 24 h with DMEM supplemented with 20% v/v FBS and 0.5 mM azF. Cells were harvested after a further 24 hrs and the membrane fraction was isolated by centrifugation. The membranes were incubated with the labelled peptide for 1 h at room temperature. Once the incubation was complete the sample was split into two equal parts. One part was pipetted into a quartz cuvette and exposed to 254 nm light for 1 h, (a longer exposure than previously reported[24]) whilst the other was wrapped in aluminium foil and also placed in the light source. Heat was dissipated in both samples using silicone tubing inserted into cuvette which was flushed with ice-cold water. Cross-linking was carried out in a UVP crosslinker (Analytik-Jena AG, Germany) at an energy of 100 $\mu J/cm^2$, with the sample approximately 10cm from the light source. Both the cross-linked and control samples were pelleted by centrifugation, washed using PBS and solubilised using dodecylmaltoside for 4 h. Post solubilisation, the samples were centrifuged at 30,000 g for 30 min after which 150 µl of the soluble fraction was pipetted into a well of a 96 well plate and read using a Mithras LB 940 (Berthould). The cross-linked and control samples were compared to determine the degree of peptide labelling.

Tyrosine mutagenesis - Individual amino acids in human HA-tagged CLR were mutated to tyrosine as described previously[11, 12, 14].

cAMP production - Human HA-tagged CLR (WT or mutant) and myc-tagged RAMP1 were transfected into HEK293T or HEK293S cells, stimulated with human alpha CGRP or

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

synthetic peptides and cAMP accumulation measured via Alpha Screen, or LANCE as previously described[11, 13, 30].

Radioligand binding **–** Competition radioligand binding assays were performed on HEK293S membranes using ^{125}I-hαCGRP. HEK293S cells were grown in 15 cm dishes, each dish was transfected with 30 µg of human HA-tagged CLR and 30 µg myc-tagged RAMP1 using polyethyleneimine (PEI) as described previously[13]. 48 hours after transfection membranes were isolated by homogenising cells followed by centrifugation at 100,000 x g for 1 hour at 4° C, membranes were resuspended and stored at -80 °C. The binding assay was performed essentially as described previously[31] except the membranes were incubated with labelled and unlabelled peptides for 1 hour at room temperature.

Data analysis **-** Concentration response curves were fitted to a three parameter logistic equation to obtain Emax, pEC_{50} and basal responses. The Hill coefficient was constrained to unity. Curve fitting was by GraphPad Prism v7, as described previously[13]. For the photoaffinity cross-linking, paired Student t-tests were used to assess if the total cross-linking for each mutant was statistically different from the non-specific, accepting significance at $P<0.05$.

Molecular modelling **-** Homology models of the active CLR were generated using Modeller[32] utilising the recently solved cryo-electron microscope structures of the activated GLP-1 and calcitonin receptors (PDB codes 5VAI and 5UZ7, respectively)[8, 9] . One thousand models combining homology-based restraints from both templates (>2Å RMSD between models) were generated by Modeller using the default method. The transmembrane and loop regions of the Modeller based structures were further refined and ranked using the membrane relax module of ROSETTA[33]. The refined models were clustered and the best model was chosen based on the largest cluster with the lowest ROSETTA membrane score.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The peptide was initially *ab initio* folded using an in-house script with a disulfide bond constraining the Cys2 and Cys7 of the peptide. Regions of secondary structure[34] were also imposed on the *ab initio* simulation. The best scoring folded peptide was docked based on the FlexPepDock module of ROSETTA. 10,000 docking solutions between the peptide and receptor were generated. The FlexPepDock docked solutions were filtered in 2 stages. The docked solutions were initially filtered using analogous contact restraints (cutoff of 5Å) as observed in the 4RWG crystal structure[9]. These results were further filtered by keeping any solution in which both Ile^{284} and Leu^{291} were within 5Å of any atom of the docked CGRP ligand. The filtered results (737 docked poses) were then further refined using the membrane relax module also found in the ROSETTA suite of software. The middle structure of the largest, lowest energy cluster was chosen for further analysis.

Replica Exchange Monte Carlo simulations as implemented in Hippo[35] were used explore the conformational space of the ROSETTA refined model. 16 replicas were simulated at temperatures spanning 300K-500K following a Boltzmann distribution in a 30 Å implicit membrane. Other variables were kept as the default settings. The trajectory was visualised using Visual Molecular Dynamics[36].

RESULTS

Activity of [Lys(5,(6)-carboxyfluoroscein)[15]] human alpha CGRP (15-Fluo CGRP) -To identify cross-linking to CLR, a fluorescent CGRP agonist was required. Based on previously published structure-activity data[37], supported by molecular modelling[11, 38] we reasoned that it should be possible to modify CGRP at position 15 whilst retaining agonist activity. The native Leu at this residue was replaced by Lys and derivatised with 5,(6)-carboxyfluorescein. The resulting analogue was evaluated for its ability to stimulate cAMP production via the CGRP receptor. Whilst it had reduced potency, it was a full agonist (Figure 1) suggesting that this modification did not greatly affect the functional properties of ligand



Figure 1. cAMP production on HEK293T cells transfected with CLR and RAMP1 and exposed to CGRP or 15-Fluo-CGRP for 15 min. Values are means ± S.E.M., n=3 independent experiments.

Confirmation of cross-linking strategy - Preliminary experiments indicated that optimal specific cross-linking was obtained following 1h exposure to uv light. The availability of a crystal structure showing the binding of a modified CGRP analogue to the extracellular domain of the CGRP receptor[10] provided a system to evaluate our methodology. A series of

azF mutants was constructed in which residues, within 5 Å or further than 7 Å from the bound CGRP analogue were substituted. There was excellent agreement between the ability of the mutants to cross-link to CGRP and their distances from the bound CGRP analogue in the crystal structure (Figure 2).



Figure 2. Fluorescence of solubilised HEK293T cell membranes from cells transfected with RAMP1 and CLR containing azF substitutions at the indicated residues. Membranes were exposed to 15-Fluo CGRP in the presence or absence of uv light. D94, H114, W121 and N128 are all within 5 Å of bound CGRP[10]; other residues are 7-10 Å away. Values are means ± S.E.M., n=3. *P<0.05, **P<0.01; values of total labelling significantly different from the non-specific in the paired control samples i.e. absence of uv light.

Cross-linking by residues in ECL2 **-** A scan was then carried out on ECL2 of CLR and its flanking regions from H270 to Y292, excluding C282 which is involved in a conserved disulfide bond with C212 at the extracellular end of TM3. The data suggest that major points of attachment for 15-Fluo CGRP are I284 and L291, with much smaller although significant

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

labelling in a number of other positions at the distal end of the loop (Figure 3). There was virtually no specific labelling at any position in the loop proximal to D280. It is possible that a lack of labelling might simply reflect that the receptor is non-functional when substituted with azF. To test this, a Tyr scan of the residues mutated to azF was carried out, excluding the native tyrosines at positions 277 and 278 (Figure 4). A Tyr rather than an azF scan was carried out because the modified aminoacyl t-RNA synthetase used to incorporate azF will also accept Tyr, albeit at lower efficiency, resulting in a mixed population of receptors potentially with one of two different residues at the same site[24]. Tyr is structurally the closest natural amino acid to azF. The results showed that all the mutants assessed should still be able to interact with 15-Fluo CGRP at 100 nM, the concentration used in our cross-linking experiments, as the Tyr mutants retained a good sensitivity to CGRP.



Figure 3. Fluorescence of solubilised HEK293T cell membranes from cells transfected with RAMP1 and CLR containing azF substitutions at the indicated residues. Membranes were exposed to 15-Fluo CGRP in the presence or absence of uv light. The values are the specific labelling, following subtraction of the non-specific from total bound fluorescence. Values are means ± S.E.M., n=3-6. *, $P<0.05$; values where total labelling is significantly different from

the non-specific in the paired control samples i.e. absence of uv light. Non-specific labelling ranged from 2247 to 5759 AU.



Figure 4 Tyrosine scan of ECL2. Potency of human alpha CGRP at stimulating cAMP production in HEK293T cells transfected with CLR (WT or mutants) and RAMP1. Values are means ± S.E.M., n=3.

Role of TMs 3 and 6 - The current cross-linking data and previous mutation studies have indicated that ECL2 and the first turn of TM5 are important in forming the binding site for CGRP. We extended the use of our cross-linking method to address the role of other parts of the receptor. M223 (TM3) and F349 (TM6) were mutated to azF. These residues are likely to face into the TM bundle of CLR but they are approximately two helical turns deeper into the TM bundle than L291 (Figure 6). Thus they give insight into how far CGRP penetrates into the TM core of CLR. The specific cross-linking seen with both of these residues was

1
2
3 comparable with that of S286 (Figure 5), which appears to act as a minor contact in ECL2
4
5 (Figure 3), although we cannot exclude a lower cross-linking efficiency due to poor
6
7 photolysis of residues deep in the TM bundle. It seems likely that M223 and F349 are at the
8
9 base of the binding pocket for CGRP.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32



33 Figure 5. Fluorescence of solubilised HEK293T cell membranes from cells transfected with
34
35 RAMP1 and CLR containing azF substitutions at the indicated residues. Membranes were
36
37 exposed to 15-Fluo CGRP in the presence or absence of uv light. Values are means ± S.E.M.,
38
39 n=3. *P<0.05; values of total labelling significantly different from the non-specific in the
40
41 paired control samples i.e. absence of uv light.
42
43
44
45
46
47 ***Molecular modelling of bound CGRP*** – Our modelling suggests that CGRP extends down as
48
49 far as H295, in TM5. I284 is close to Leu12 and Ala13 of CGRP and L291 is adjacent to
50
51 Thr6 of CGRP (Figure 6). Leu16 of CGRP is the most proximal residue of the bound CGRP
52
53 to make potential contact with the ECLs. It is close to I284 and V198 (in ECL1) but is also in
54
55 proximity to I32 of the ECD, perhaps making contact with both ECLs and the ECD of CLR.
56
57
58
59
60



Figure 6. Molecular model of the CLR (brown ribbon)/RAMP1 (blue ribbon; TM region omitted for clarity) complex with bound CGRP (pink ribbon). A, Detail of predicted CGRP interactions with I284 and L291. B The predicted position of bound CGRP with residues on the periphery of the binding site. CLR residues shown as spacefill; CGRP residues shown in green. The models can be viewed online using Molecule Viewer[39] at https://bit.ly/2FnQAHp. (Recommended browsers are Google Chrome in incognito mode or Firefox). C, Full length structure of the CLR complex. The positions of TM5 and Helix 8 are highlighted to aid orientation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Activity of [Leu12Ala]- and [Leu16Ala]-human alpha CGRP - To further test our proposed mode of binding, we investigated the ability of [Leu12Ala]- and [Leu16Ala]-human alpha CGRP to stimulate cAMP. Both analogues showed substantial reductions in potency and E_{max}, with [Leu16Ala]-human alpha CGRP showing the largest effects (Figure 7). This result was confirmed in a radioligand binding assay, where [Leu16Ala]- human alpha CGRP also showed a substantial reduction in affinity.



Figure 7. Comparison of the ability of [Leu12Ala]- and [Leu16Ala]-human alpha CGRP to A, stimulate cAMP in HEK293S cells transfected with HA-CLR and myc-RAMP1 or B, displace ^{125}I-CGRP at the CGRP receptor. Values are means ± S.E.M., n=3-4.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

We have used unnatural amino acid mutagenesis to map key residues in and adjacent to ECL2 of CLR that contribute to the binding of CGRP. The data suggest that I284 and L291 make contacts in the vicinity of Thr6 and Leu12 of bound CGRP. This binding orientation is consistent with the modelled position of calcitonin in the cryo-electron microscopy structure of the calcitonin receptor[9].

A number of the residues that we have identified in this study as contributing to the binding of CGRP have been previously identified as important for CGRP production of cAMP, based on mutagenesis. We predicted that I284 could interact with one or more CGRP residues C-terminal to the 2-7 disulfide-bonded loop of the peptide, conventionally considered to be the mediator of receptor activation[13]. However, using an alanine scan we have previously found that changes to Val8 and Thr9 of CGRP can alter its efficacy[25]. Our current model suggests that Val8 is adjacent to H194 in TM2 and Thr9 is in proximity to the backbone of ECL2. Our study further extends this by demonstrating that Leu16 in CGRP can influence efficacy, potentially by contacting I32 in the ECD of CLR. Furthermore, we have observed during a replica exchange Monte Carlo simulation of the bound CGRP (to investigate dynamic stability), L16 periodically interacts with V198 (ECL1) and I284 of CLR. V198 and I32 have both been shown to be important for cAMP production by CGRP[40, 41]. These observations suggest how CGRP residues outside of the classic 1-7 “activation” domain of the peptide can influence efficacy; we speculate that Leu16 may be of particular importance in interacting with both the ECLs and ECD of CLR. It may therefore be possible to develop truncated analogues that retain agonist activity by interacting with the upper regions of the TM bundle and ECLs, as has been done for GLP-1[42].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Within the 1-7 region of CGRP, our previous structure-activity work indicated that Thr6 was essential for agonism. In fact this residue is absolutely conserved in all members of the calcitonin family of peptides[25, 34]. In our model, Thr6 of CGRP is close not only to L291 of TM5 but also H295 a turn lower. Previous mutagenesis has shown that H295 is important for the activation of all CLR/RAMP complexes with both CGRP and adrenomedullin[11]; its equivalent is also important for agonism by calcitonin in the calcitonin receptor[9]. Molecular dynamics simulations indicated that H295, at the top of TM5, controls interhelical contacts between TMs 3, 5, 6 and 7 of CLR. A rotation of this residue caused helix sliding and tilting that opened the G protein binding pocket[11]. Residues deeper in the receptor which are important for receptor activation such as E348[11] would seem unlikely to be significant ligand contacts, unless they are connected by bound water molecules.

Although I284 and L291 were the main contacts revealed in this study, it is interesting to note that there were a range of minor contacts in the distal part of ECL2. The pattern here was that every other residue I284 and L290 appeared as contacts. Interestingly, our previous mutagenesis and modelling has suggested that this forms a short stretch of beta-strand, along the rim of the cavity between TMs 4 and 5[12]. This secondary structure element is consistent with the labelling pattern.

In eight out fifteen of the human family B GPCRs, the equivalent of I284 is glutamic or aspartic acid; in a further three receptors it is threonine. Only in CLR, the calcitonin receptor (leucine) and the corticotrophin receptors (phenylalanine) is the corresponding residue hydrophobic. Thus within family B GPCRs this residue may be important in ligand

specificity; it faces into the core of the receptor where it can be resolved in structures. In the calcitonin receptor, the equivalent residue is important for the binding of human and porcine but not salmon calcitonin, indicating how similar ligands can differentially interact with residues within their binding pockets[43]. The absence of labelling for W283 is noteworthy as this residue is highly conserved in family B GPCRs and mutation may show deleterious effects[44, 45]. Its side-chain orientation is variable in the current family B GPCR structures, either facing into the core or in the calcitonin and glucagon receptor structures or inserting between TM3 and TM4 in other structures[4, 5, 9 46]. These data suggest that W283 does not contact the peptide, indicating it is most likely to be inserted between TMs 3 and 4 (Fig 6B).

The techniques described in this paper may be applied to other receptors. Whilst previously the method has been applied to the GLP-1 receptor[24], our experience is that significant refinement is required. In the current study, it was necessary to illuminate the receptor for 1 h to get cross-linking, rather than for the 5 min used in the GLP-1 study. This difference may reflect that the GLP-1 study was focused on the extracellular domain of the receptor; greater exposure times may be necessary for residues within the membrane domain. In studies of the CRF1R, where transmembrane residues were also targeted, illumination was for 20 to 40 mins[21, 22]. Thus, investigators should optimise labelling conditions to ensure their protocols are maximally effective. The cross-linking efficiency will also depend on the power of the UV source and the distance of the sample from the light, which are likely to vary between laboratories.

In conclusion, the current study suggests that CGRP binds to a pocket formed by the ECLs of CLR, penetrating approximately two turns into the TM region. Direct contacts with residues

here and in the ECLs form the basis of the agonist-induced conformation shift in CLR during receptor activation.

ACKNOWLEDGEMENTS

We thank Dr Casandra Koole and Dr Harriet Watkins for advice. Furthermore, we thank Merry Wang at Autodesk for help and advice with Molecule Viewer.

FUNDING SOURCES

This work was supported by BBSRC grants to DRP (BB/M007529/1) and CAR (BB/M006883/1). CAR is a Royal Society Industry Fellow. DLH is a James Cook Research Fellow of the Royal Society of New Zealand.

AUTHOR INFORMATION

Corresponding Author

David R. Poyner, School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK; d.r.poyner@aston.ac.uk,

Author Contributions

The manuscript was written through contributions of all authors. JS, RU, JJG and MLG performed experiments. TS provided constructs for photoaffinity labelling and technical advice. PWH and MAB synthesized peptides. JS, CAR, TS, DRP and DLH interpreted experiments and wrote the paper. All authors have given approval to the final version of the manuscript.

REFERENCES

[1] Hay, D. L., Garelja, M. L., Poyner, D. R., and Walker, C. S. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25, *Br J Pharmacol 175*, 3-17.
[2] Hay, D. L., and Walker, C. S. (2017) CGRP and its receptors, *Headache 57*, 625-636.
[3] Hoare, S. R. (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors., *Drug Discov Today 10*, 417-427.
[4] Zhang, H., Qiao, A., Yang, D., Yang, L., Dai, A., de Graaf, C., Reedtz-Runge, S., Dharmarajan, V., Zhang, H., Han, G. W., Grant, T. D., Sierra, R. G., Weierstall, U., Nelson, G., Liu, W., Wu, Y., Ma, L., Cai, X., Lin, G., Wu, X., Geng, Z., Dong, Y., Song, G., Griffin, P. R., Lau, J., Cherezov, V., Yang, H., Hanson, M. A., Stevens, R. C., Zhao, Q., Jiang, H., Wang, M. W., and Wu, B. (2017) Structure of the full-length glucagon class B G-protein-coupled receptor, *Nature 546*, 259-264.
[5] Jazayeri, A., Rappas, M., Brown, A. J. H., Kean, J., Errey, J. C., Robertson, N. J., Fiez-Vandal, C., Andrews, S. P., Congreve, M., Bortolato, A., Mason, J. S., Baig, A. H., Teobald, I., Dore, A. S., Weir, M., Cooke, R. M., and Marshall, F. H. (2017) Crystal structure of the GLP-1 receptor bound to a peptide agonist, *Nature 546*, 254-258.
[6] Zhang, H., Qiao, A., Yang, L., Van Eps, N., Frederiksen, K. S., Yang, D., Dai, A., Cai, X., Zhang, H., Yi, C., Cao, C., He, L., Yang, H., Lau, J., Ernst, O. P., Hanson, M. A., Stevens, R. C., Wang, M. W., Reedtz-Runge, S., Jiang, H., Zhao, Q., and Wu, B. (2018) Structure of the glucagon receptor in complex with a glucagon analogue, *Nature 553*, 106-110.
[7] Liang, Y. L., Khoshouei, M., Glukhova, A., Furness, S. G. B., Zhao, P., Clydesdale, L., Koole, C., Truong, T. T., Thal, D. M., Lei, S., Radjainia, M., Danev, R., Baumeister, W., Wang, M. W., Miller, L. J., Christopoulos, A., Sexton, P. M., and Wootten, D. (2018) Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex, *Nature 555*, 121-125.
[8] Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., and Skiniotis, G. (2017) Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein, *Nature 546*, 248-253.
[9] Liang, Y. L., Khoshouei, M., Radjainia, M., Zhang, Y., Glukhova, A., Tarrasch, J., Thal, D. M., Furness, S. G. B., Christopoulos, G., Coudrat, T., Danev, R., Baumeister, W., Miller, L. J., Christopoulos, A., Kobilka, B. K., Wootten, D., Skiniotis, G., and Sexton, P. M. (2017) Phase-plate cryo-EM structure of a class B GPCR-G-protein complex, *Nature 546*, 118-123.
[10] Booe, J. M., Walker, C. S., Barwell, J., Kuteyi, G., Simms, J., Jamaluddin, M. A., Warner, M. L., Bill, R. M., Harris, P. W., Brimble, M. A., Poyner, D. R., Hay, D. L., and Pioszak, A. A. (2015) Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor, *Molecular cell 58*, 1040-1052.
[11] Woolley, M. J., Reynolds, C. A., Simms, J., Walker, C. S., Mobarec, J. C., Garelja, M. L., Conner, A. C., Poyner, D. R., and Hay, D. L. (2017) Receptor activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide and adrenomedullin receptors to Gs, *Biochem Pharmacol 142*, 96-110.
[12] Woolley, M. J., Simms, J., Mobarec, J. C., Reynolds, C. A., Poyner, D. R., and Conner, A. C. (2017) Understanding the molecular functions of the second extracellular loop (ECL2) of the calcitonin gene-related peptide (CGRP) receptor using a comprehensive mutagenesis approach, *Mol Cell Endocrinol 454*, 39-49.
[13] Woolley, M. J., Simms, J., Uddin, S., Poyner, D. R., and Conner, A. C. (2017) Relative Antagonism of Mutants of the CGRP Receptor Extracellular Loop 2 Domain (ECL2) Using a Truncated Competitive Antagonist (CGRP8-37): Evidence for the Dual Involvement of ECL2 in the Two-Domain Binding Model, *Biochemistry 56*, 3877-3880.
[14] Woolley, M. J., Watkins, H. A., Taddese, B., Karakullukcu, Z. G., Barwell, J., Smith, K. J., Hay, D. L., Poyner, D. R., Reynolds, C. A., and Conner, A. C. (2013) The role of ECL2 in CGRP receptor

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

activation: a combined modelling and experimental approach, *Journal of the Royal Society, Interface / the Royal Society 10*, 20130589.

[15] Vohra, S., Taddese, B., Conner, A. C., Poyner, D. R., Hay, D. L., Barwell, J., Reeves, P. J., Upton, G. J., and Reynolds, C. A. (2013) Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies, *Journal of the Royal Society, Interface / the Royal Society 10*, 20120846.

[16] Dong, M., and Miller, L. J. (2006) Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor, *Ann N Y Acad Sci 1070*, 248-264.

[17] Wang, L., Brock, A., Herberich, B., and Schultz, P. G. (2001) Expanding the genetic code of Escherichia coli, *Science 292*, 498-500.

[18] Grunbeck, A., and Sakmar, T. P. (2013) Probing G protein-coupled receptor-ligand interactions with targeted photoactivatable cross-linkers, *Biochemistry 52*, 8625-8632.

[19] Valentin-Hansen, L., Park, M., Huber, T., Grunbeck, A., Naganathan, S., Schwartz, T. W., and Sakmar, T. P. (2014) Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid, *J Biol Chem 289*, 18045-18054.

[20] Park, M., Sivertsen, B. B., Els-Heindl, S., Huber, T., Holst, B., Beck-Sickinger, A. G., Schwartz, T. W., and Sakmar, T. P. (2015) Bioorthogonal Labeling of Ghrelin Receptor to Facilitate Studies of Ligand-Dependent Conformational Dynamics, *Chem Biol 22*, 1431-1436.

[21] Coin, I., Katritch, V., Sun, T., Xiang, Z., Siu, F. Y., Beyermann, M., Stevens, R. C., and Wang, L. (2013) Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR, *Cell 155*, 1258-1269.

[22] Seidel, L., Zarzycka, B., Zaidi, S. A., Katritch, V., and Coin, I. (2017) Structural insight into the activation of a class B G-protein-coupled receptor by peptide hormones in live human cells, *Elife 6*, pii: e27711.

[23] Coin, I., Perrin, M. H., Vale, W. W., and Wang, L. (2011) Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison, *Angew Chem Int Ed Engl 50*, 8077-8081.

[24] Koole, C., Reynolds, C. A., Mobarec, J. C., Hick, C., Sexton, P. M., and Sakmar, T. P. (2017) Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R), *J Biol Chem 292*, 7131-7144.

[25] Hay, D. L., Harris, P. W., Kowalczyk, R., Brimble, M. A., Rathbone, D. L., Barwell, J., Conner, A. C., and Poyner, D. R. (2014) Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation, *Br J Pharmacol 171*, 415-426.

[26] Wöhr, T., and Mutter, M. (1995) Pseudo-prolines in peptide synthesis: Direct insertion of serine and threonine derived oxazolidines in dipeptides, *Tetrahedron Lett. 36*, 3847-3848.

[27] Fischer, R., Mader, O., Jung, G., and Brock, R. (2003) Extending the Applicability of Carboxyfluorescein in Solid-Phase Synthesis, *Bioconjugate Chem. 14*, 653-660.

[28] Harris, P. W. R., Lee, D. J., and Brimble, M. A. (2012) A slow gradient approach for the purification of synthetic polypeptides by reversed phase high performance liquid chromatography, *J. Pept. Sci. 18*, 549-555.

[29] Ye, S., Kohrer, C., Huber, T., Kazmi, M., Sachdev, P., Yan, E. C., Bhagat, A., RajBhandary, U. L., and Sakmar, T. P. (2008) Site-specific incorporation of keto amino acids into functional G protein-coupled receptors using unnatural amino acid mutagenesis, *J Biol Chem 283*, 1525-1533.

[30] Garelja, M. L., Walker, C. A., Siow, A., Yang, S. H., Harris, P. W. R., Brimble, M. A., Watkins, H. A., Gingell, J. J., and Hay, D. L. (2018) Receptor Activity Modifying Proteins Have Limited Effects on the Class B G Protein-Coupled Receptor Calcitonin Receptor-Like Receptor Stalk, *Biochemistry 57*, 1410-1422.

[31] Qi, T., Christopoulos, G., Bailey, R. J., Christopoulos, A., Sexton, P. M., and Hay, D. L. (2008) Identification of N-terminal receptor activity-modifying protein residues important for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

calcitonin gene-related peptide, adrenomedullin, and amylin receptor function, *Mol Pharmacol 74*, 1059-1071.

[32] Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints, *J Mol Biol 234*, 779-815.

[33] Barth, P., Schonbrun, J., and Baker, D. (2007) Toward high-resolution prediction and design of transmembrane helical protein structures, *Proc Natl Acad Sci U S A 104*, 15682-15687.

[34] Watkins, H. A., Rathbone, D. L., Barwell, J., Hay, D. L., and Poyner, D. R. (2013) Structure-activity relationships for alpha-calcitonin gene-related peptide, *Br J Pharmacol 170*, 1308-1322.

[35] Ulmschneider, J. P., and Ulmschneider, M. B. (2009) Sampling efficiency in explicit and implicit membrane environments studied by peptide folding simulations, *Proteins 75*, 586-597.

[36] Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD - Visual Molecular Dynamics, *J. Molec. Graphics 14*, 33-38.

[37] Howitt, S. G., Kilk, K., Wang, Y., Smith, D. M., Langel, U., and Poyner, D. R. (2003) The role of the 8-18 helix of CGRP8-37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions, *Br J Pharmacol 138*, 325-332.

[38] Watkins, H. A., Chakravarthy, M., Abhayawardana, R. S., Gingell, J. J., Garelja, M., Pardamwar, M., McElhinney, J. M., Lathbridge, A., Constantine, A., Harris, P. W., Yuen, T. Y., Brimble, M. A., Barwell, J., Poyner, D. R., Woolley, M. J., Conner, A. C., Pioszak, A. A., Reynolds, C. A., and Hay, D. L. (2016) Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular Properties, *J Biol Chem 291*, 11657-11675.

[39] Balo, A. R., Wang, M., and Ernst, O. P. (2017) Accessible virtual reality of biomolecular structural models using the Autodesk Molecule Viewer, *Nat Methods 14*, 1122-1123.

[40] Barwell, J., Conner, A., and Poyner, D. R. (2011) Extracellular loops 1 and 3 and their associated transmembrane regions of the calcitonin receptor-like receptor are needed for CGRP receptor function, *Biochim Biophys Acta 1813*, 1906-1916.

[41] Barwell, J., Miller, P. S., Donnelly, D., and Poyner, D. R. (2010) Mapping interaction sites within the N-terminus of the calcitonin gene-related peptide receptor; the role of residues 23-60 of the calcitonin receptor-like receptor, *Peptides 31*, 170-176.

[42] Hoang, H. N., Song, K., Hill, T. A., Derksen, D. R., Edmonds, D. J., Kok, W. M., Limberakis, C., Liras, S., Loria, P. M., Mascitti, V., Mathiowetz, A. M., Mitchell, J. M., Piotrowski, D. W., Price, D. A., Stanton, R. V., Suen, J. Y., Withka, J. M., Griffith, D. A., and Fairlie, D. P. (2015) Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists, *J Med Chem 58*, 4080-4085.

[43] Dal Maso, E., Zhu, Y., Pham, V., Reynolds, C. A., Deganutti, G., Hick, C. A., Yang, D., Christopoulos, A., Hay, D. L., Wang, M. W., Sexton, P. M., Furness, S. G. B., and Wootten, D. (2018) Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy, *Biochem Pharmacol 150*, 214-244.

[44] Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., Simms, J., Sridhar, R., Furness, S. G., Liu, M., Thompson, P. E., Miller, L. J., Christopoulos, A., and Sexton, P. M. (2016) The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism, *Cell 165*, 1632-1643.

[45] Gkountelias, K., Tselios, T., Venihaki, M., Deraos, G., Lazaridis, I., Rassouli, O., Gravanis, A., and Liapakis, G. (2009) Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding, *Mol Pharmacol 75*, 793-800.

[46] Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K., Dore, A. S., Jazayeri, A., Cooke, R. M., Weir, M., and Marshall, F. H. (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1, *Nature 499*, 438-443.